Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 2:40 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 532989 | NSE: BAFNAPH

Bafna Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹55.95Overvalued by 50.04%vs CMP ₹112.00

P/E (23.1) × ROE (7.7%) × BV (₹38.60) × DY (2.00%)

₹53.57Overvalued by 52.17%vs CMP ₹112.00
MoS: -109.1% (Negative)Confidence: 65/100 (Moderate)Models: All 8: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹63.2525%Over (-43.5%)
Graham NumberEarnings₹59.5318%Over (-46.8%)
Earnings PowerEarnings₹11.7212%Over (-89.5%)
DCFCash Flow₹65.7615%Over (-41.3%)
Net Asset ValueAssets₹38.888%Over (-65.3%)
EV/EBITDAEnterprise₹67.6210%Over (-39.6%)
Earnings YieldEarnings₹40.808%Over (-63.6%)
Revenue MultipleRevenue₹61.716%Over (-44.9%)
Consensus (8 models)₹53.57100%Overvalued
Key Drivers: Wide model spread (₹12–₹68) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 13.0%

*Investments are subject to market risks

Investment Snapshot

54
Bafna Pharmaceuticals Ltd scores 54/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health54/100 · Moderate
ROCE 8.3% AverageROE 7.7% AverageD/E 1.39 High debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 0.81% (6mo) Slight increasePromoter holding at 75.0% Stable
Earnings Quality40/100 · Moderate
OPM contracting (14% → 8%) Declining
Quarterly Momentum70/100 · Strong
Revenue (4Q): -1% YoY FlatProfit (4Q): +1,988% YoY Strong
Industry Rank55/100 · Moderate
P/E 23.1 vs industry 53.8 Cheaper than peersROCE 8.3% vs industry 16.4% Below peers3Y sales CAGR: 20% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Bafna Pharmaceuticals Ltd Investor Signals

Computed from valuation, cash flow, balance sheet, ownership and quarterly trend data already available in this stock page.

Value Trap Score
90/100
High
Derived from: Cheapness + weak quality + weak cash support
Current data: P/E 23.1 vs Ind 53.8 | ROCE 8.3% | ROE 7.7% | CFO/NP N/A
Balance Sheet Stress
30/100
Comfortable
Derived from: Leverage + debt servicing + liquidity + debt trend
Current data: D/E 1.39x | IntCov 0.0x | Current 1.29x | Borrow/Reserve 0.47x
Cash Flow Reliability
29/100
Weak
Derived from: Cash backing of earnings + working capital pressure
Current data: CFO ₹0 Cr | NP ₹4 Cr | CFO/NP N/A
Ownership Accumulation
0
Neutral
Derived from: FII + DII + promoter direction, adjusted by crowding
Current data: FII 0.00 pp | DII N/A | Prom 0.00 pp
Business Momentum
-17
Early weakness
Derived from: Latest quarter sales + profit + OPM change
Current data: Q Sales +2.5% | Q NP -8.0% | Q OPM -2.6 pp
Derived FieldValueHow it is derived
Valuation Gap %-52.2%((Fair Value - CMP) / CMP) × 100
Borrowings / Reserves0.47xLatest borrowings divided by latest reserves
CFO / Net ProfitN/ALatest operating cash flow divided by latest net profit
FII Change0.00 ppLatest FII% minus previous FII%
DII ChangeN/ALatest DII% minus previous DII%
Promoter Change0.00 ppLatest promoter% minus previous promoter%
Shareholder Count Change-453Latest shareholder count minus previous count
Quarterly Sales Change+2.5%Latest quarter sales vs previous quarter sales
Quarterly Profit Change-8.0%Latest quarter net profit vs previous quarter net profit
Quarterly OPM Change-2.6 ppLatest quarter OPM minus previous quarter OPM

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 2:40 am

Market Cap 265 Cr.
Current Price 112
Intrinsic Value₹53.57
High / Low 205/70.6
Stock P/E23.1
Book Value 38.6
Dividend Yield0.00 %
ROCE8.34 %
ROE7.69 %
Face Value 10.0
PEG Ratio1.77

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Bafna Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Bafna Pharmaceuticals Ltd 265 Cr. 112 205/70.623.1 38.60.00 %8.34 %7.69 % 10.0
BDH Industries Ltd 219 Cr. 381 524/24121.0 1231.18 %17.8 %14.2 % 10.0
Everest Organics Ltd 215 Cr. 221 536/19736.7 74.70.00 %1.76 %2.23 % 10.0
Gennex Laboratories Ltd 208 Cr. 8.55 17.2/7.0511.9 8.790.00 %13.0 %10.2 % 1.00
Ambalal Sarabhai Enterprises Ltd 203 Cr. 26.5 42.0/23.111.4 19.20.00 %9.12 %6.25 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Bafna Pharmaceuticals Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 21.9634.2242.2441.9540.6828.4441.4033.2940.3233.1939.0634.6235.47
Expenses 19.4231.1834.6235.6636.6730.5138.5132.0836.5330.1335.9529.5531.19
Operating Profit 2.543.047.626.294.01-2.072.891.213.793.063.115.074.28
OPM % 11.57%8.88%18.04%14.99%9.86%-7.28%6.98%3.63%9.40%9.22%7.96%14.64%12.07%
Other Income 0.641.930.261.870.160.980.520.161.020.18-0.760.601.18
Interest 0.450.580.700.600.440.580.680.650.620.640.820.910.86
Depreciation 1.121.401.531.211.241.271.271.441.581.660.221.371.47
Profit before tax 1.612.995.656.352.49-2.941.46-0.722.610.941.313.393.13
Tax % 0.00%0.00%4.96%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Net Profit 1.613.005.376.352.48-2.941.46-0.722.620.951.313.393.12
EPS in Rs 0.681.272.272.681.05-1.240.62-0.301.110.400.551.431.32

Last Updated: January 2, 2026, 8:31 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 23, 2026, 12:35 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 17710085654644427185115152146147
Expenses 15611682708157416173100141135132
Operating Profit 21-163-5-35-131101216111116
OPM % 12%-16%3%-8%-77%-30%3%14%14%14%7%8%11%
Other Income 14011310-231-03412
Interest 12121211720112233
Depreciation 8544433455555
Profit before tax 26-13-19-14-18-2565127410
Tax % 40%-0%-3%-4%15%8%0%0%0%2%0%0%
Net Profit 16-12-18-16-20-2565117410
EPS in Rs 0.723.28-6.53-9.90-6.95-8.34-106.532.462.214.793.111.754.08
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)500.00%-300.00%-50.00%11.11%-25.00%-25.00%124.00%-16.67%120.00%-36.36%-42.86%
Change in YoY Net Profit Growth (%)0.00%-800.00%250.00%61.11%-36.11%0.00%149.00%-140.67%136.67%-156.36%-6.49%

Bafna Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:4%
5 Years:28%
3 Years:20%
TTM:2%
Compounded Profit Growth
10 Years:8%
5 Years:40%
3 Years:-5%
TTM:1498%
Stock Price CAGR
10 Years:15%
5 Years:34%
3 Years:-4%
1 Year:25%
Return on Equity
10 Years:-10%
5 Years:11%
3 Years:11%
Last Year:8%

Last Updated: September 5, 2025, 12:15 am

Balance Sheet

Last Updated: December 4, 2025, 1:00 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 1919191924242242424242424
Reserves 5053412617-349333850576168
Borrowings 9964808247463151123242832
Other Liabilities 54504540405417141733424037
Total Liabilities 223185185167128121718690130148153161
Fixed Assets 63494743403735363940405965
CWIP 000000010212715
Investments 1181818110000000
Other Assets 158118120106868236505188958781
Total Assets 223185185167128121718690130148153161

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 19-314-7-1-34-14105922
Cash from Investing Activity + -556-1-838433-5-7-7-15-21
Cash from Financing Activity + -14-664-5-31-2712-510-11
Net Cash Flow -18-00-0006-7-28-62
Free Cash Flow -12-52040-1-36-202-2-60
CFO/OP 6%-74%-106%-263%20%8%-2,786%-132%83%32%87%194%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-78.00-80.00-77.00-87.00-82.00-59.00-2.00-5.001.00-7.00-13.00-17.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 192303291302195208524963130109101
Inventory Days 786692118102122208154185129125127
Days Payable 116149169164265517229107113165149140
Cash Conversion Cycle 15522021425531-1883196135948488
Working Capital Days 4156125-36-108-210891211231049274
ROCE %9%-13%-0%-6%-35%-21%-3%10%11%16%9%8%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 89.99%89.99%88.73%88.42%88.29%88.29%88.29%88.29%75.00%75.00%75.00%75.00%
FIIs 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%8.53%9.34%9.34%9.34%
Public 10.00%10.00%11.27%11.57%11.70%11.71%11.70%11.70%16.47%15.66%15.66%15.66%
No. of Shareholders 7,1206,9927,3547,3677,5397,3917,2957,2147,1427,2837,5727,119

Shareholding Pattern Chart

No. of Shareholders

Bafna Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 20Mar 19Mar 18Mar 17Mar 16
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) -15.52-11.48-7.15-10.43-8.80
Diluted EPS (Rs.) -15.52-11.48-7.15-10.43-8.80
Cash EPS (Rs.) -89.52-6.29-5.47-8.17-5.51
Book Value[Excl.RevalReserv]/Share (Rs.) -17.597.9715.7322.5730.95
Book Value[Incl.RevalReserv]/Share (Rs.) -17.597.9715.7322.5730.95
Revenue From Operations / Share (Rs.) 179.5418.3319.9434.8245.73
PBDIT / Share (Rs.) 6.25-5.36-1.61-2.501.34
PBIT / Share (Rs.) -7.56-6.83-3.29-4.76-1.27
PBT / Share (Rs.) -103.32-7.30-6.22-10.91-8.21
Net Profit / Share (Rs.) -103.32-7.76-7.15-10.43-8.12
NP After MI And SOA / Share (Rs.) -104.54-7.98-7.07-10.23-7.52
PBDIT Margin (%) 3.48-29.26-8.05-7.182.92
PBIT Margin (%) -4.20-37.28-16.47-13.68-2.76
PBT Margin (%) -57.54-39.86-31.19-31.34-17.95
Net Profit Margin (%) -57.54-42.32-35.84-29.95-17.74
NP After MI And SOA Margin (%) -58.22-43.52-35.48-29.38-16.44
Return on Networth / Equity (%) 0.00-99.01-44.12-44.73-24.28
Return on Capital Employeed (%) -3.29-33.22-9.90-9.17-2.41
Return On Assets (%) -34.67-15.79-12.09-10.70-7.27
Long Term Debt / Equity (X) -0.711.210.610.910.60
Total Debt / Equity (X) -0.712.431.231.931.39
Asset Turnover Ratio (%) 0.440.330.300.360.44
Current Ratio (X) 2.110.680.810.941.29
Quick Ratio (X) 1.440.550.630.741.11
Inventory Turnover Ratio (X) 2.242.661.550.890.97
Interest Coverage Ratio (X) 15.48-5.97-0.54-0.400.19
Interest Coverage Ratio (Post Tax) (X) -18.72-8.10-1.44-0.69-0.16
Enterprise Value (Cr.) -3.2969.21109.10134.30133.55
EV / Net Operating Revenue (X) -0.071.602.312.071.57
EV / EBITDA (X) -2.22-5.45-28.71-28.7653.52
MarketCap / Net Operating Revenue (X) 0.040.591.400.840.65
Price / BV (X) -0.491.361.751.290.96
Price / Net Operating Revenue (X) 0.040.591.400.840.65
EarningsYield -11.80-0.72-0.25-0.34-0.25

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Bafna Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 28/03/1995 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(CIN) is L24294TN1995PLC030698 and registration number is 030698. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 145.86 Cr. and Equity Capital is Rs. 23.66 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsBafna Towers, Chennai (Madras) Tamil Nadu 600001Contact not found
Management
NamePosition Held
Mrs. S HemalathaWhole Time Director
Mr. Vinayak Dinesh DendukuriWhole Time Director
Mr. Upendar Mekala ReddyNon Exe.Non Ind.Director
Mrs. Akila C RajuNon Exe.Non Ind.Director
Ms. R ChitraInd. Non-Executive Director
Mr. Navin KumarInd. Non-Executive Director

FAQ

What is the intrinsic value of Bafna Pharmaceuticals Ltd and is it undervalued?

As of 06 April 2026, Bafna Pharmaceuticals Ltd's intrinsic value is ₹53.57, which is 52.17% lower than the current market price of ₹112.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (7.69 %), book value (₹38.6), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Bafna Pharmaceuticals Ltd?

Bafna Pharmaceuticals Ltd is trading at ₹112.00 as of 06 April 2026, with a FY2026-2027 high of ₹205 and low of ₹70.6. The stock is currently in the middle of its 52-week range. Market cap stands at ₹265 Cr..

How does Bafna Pharmaceuticals Ltd's P/E ratio compare to its industry?

Bafna Pharmaceuticals Ltd has a P/E ratio of 23.1, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Bafna Pharmaceuticals Ltd financially healthy?

Key indicators for Bafna Pharmaceuticals Ltd: ROCE of 8.34 % is on the lower side compared to the industry average of 16.35%; ROE of 7.69 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Bafna Pharmaceuticals Ltd profitable and how is the profit trend?

Bafna Pharmaceuticals Ltd reported a net profit of ₹4 Cr in Mar 2025 on revenue of ₹146 Cr. Compared to ₹5 Cr in Mar 2022, the net profit shows a declining trend.

Does Bafna Pharmaceuticals Ltd pay dividends?

Bafna Pharmaceuticals Ltd has a dividend yield of 0.00 % at the current price of ₹112.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Bafna Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports